Introduction
============

Snakebite envenomation is a global health concern and classified as a neglected tropical disease by the World Health Organization ([@CIT0017]; [@CIT0003]). Approximately 5.4 million people are victims of snakebite worldwide each year, with 81,000-138,000 deaths and over 400,000 suffering from long-term disability, constant wound care, amputations and ongoing psychological morbidity. Nearly 9,000 cases of snakebite envenomation are reported in the United States and Canada every year ([@CIT0013]; [@CIT0010]).

Venoms are extremely complex, consisting of hundreds of proteins, peptides, enzymes and non-enzymatic toxins ([@CIT0005]). Through advancements in whole genome studies, venomics has evolved to assess toxin composition directly and indirectly via proteome- or transcriptome-based methodologies. This research has shown that venom composition varies between and within species due to ontogenetic and geographical variability, and this complexity of venom has led to inconsistent antivenom potency. For example, the same antivenom produced in different geographic regions of India exhibits different therapeutic potential, indicating that the current antivenom manufacturing techniques do not adequately account for the diverse venom composition ([@CIT0015]). Restricted availability of species-specific antivenoms can be circumvented by designing and producing high potency multipurpose antivenoms effective against multiple species of snakes ([@CIT0002]). Antibody-based antivenoms are routinely prepared from the plasma of host animals immunized with venoms from multiple snake species. While this is a successful therapeutic approach for some snake species, there remain limitations in safety, efficacy, and economic aspects of manufacturing. Immediate hypersensitivity reactions following administration of Crotalidae polyvalent immune Fab antivenom, including urticaria, dyspnea, hypotension, tachycardia, chest pain, and nausea may occur in 19% of patients, and the range of serum sickness incidence including fever, myalgia, epigastric pressure, and arthralgia is 6% - 23% ([@CIT0012]). In the United States the most typical antivenom therapy using Crotalidae polyvalent immune Fab could cost more than \$18,000 and its usage can be a financial burden for patients and hospitals ([@CIT0016]). Thus, there is a need for a novel approach to develop antivenom solutions that are capable of rapid production and maximal efficacy without adverse reactions. Phage display techniques offer a comprehensive tool for the selection of phage-expressed peptides which have affinity for unique targets normally inaccessible to antibody-based methods ([@CIT0018]). Hence, a phage display technique using composite consensus targets based on venom proteomic data could lead to the development of a broad spectrum inhibitor of multiple venoms.

To demonstrate proof-of-concept of phage display for the development of venom component inhibitor, the venom of the Western cottonmouth, *Agkistrodon piscivorus leucostoma*, a venomous New World pit viper found in North and Central America ([@CIT0009]), was selected. Western cottonmouths inhabit a large geographic area and are found along the coast of the Gulf of Mexico into southeastern and central Texas, presenting a concern to civilian populations, as well as military operational and training sites across this region. Major components of the Western cottonmouth venom are phospholipases A~2~ (PLA~2~, 43.2%), metalloproteases (26.1%) and serine proteases (10.1%) ([@CIT0009]). The clinical effects of envenomation are the initiation of the coagulation cascade and blockage of neuromuscular transmission. Snake venom PLA~2~ enzymes interfere in the normal physiological processes of victim animals and induce a wide variety of pharmacological effects including neurotoxicity ([@CIT0006]), myotoxicity ([@CIT0014]), and anticoagulant effects ([@CIT0011]).

In this study, conserved PLA~2~ sequences from several species of cottonmouth snakes were identified and mapped to the three-dimensional (3D) crystal structure of PLA~2~ to determine their solvent accessibility. Phage-displayed peptides with affinity towards the target consensus sequence were tested for the generation of potential venom inhibitors.

Materials and Methods
=====================

Designing consensus sequence
----------------------------

Queries against the UniProt database were used to gather amino acid sequences of target peptides. Sequences were uploaded to Basic Local Alignment Search Tool (BLAST) to determine homologous regions using default parameters. Consensus peptides were designed based on areas of homology, and areas corresponding to active sites were given priority during the design process. The original sequences were aligned to the consensus sequence to ensure homology and identity. Once the validity of the consensus sequence was confirmed, the sequence was overlaid onto a crystal structure of the target protein. Crystal structure information was unavailable for Western cottonmouth PLA~2~, thus Eastern cottonmouth PLA~2~ (PBD: 1PPA) was used to map consensus sequence. JSmol Viewer, an open-source Java viewer, from Research Collaboratory for Structural Bioinformatics Protein Data Bank ([@CIT0001]) was used to visualize the 3D mapping of the solvent exposed regions of the target peptide.

Screening of peptides with affinity to the consensus sequence
-------------------------------------------------------------

A cleavable crosslinker, Sulfo-LC-SPDP (sulfosuccinimidyl 6-\[3'-(2-pyridyldithio)propionamido\]hexanoate) was used to bind the target peptide to the interior of an aminosilylated glass capillary tube. Briefly, a glass capillary tube was washed with acetone and treated with aminosilane reagent. The silylated glass capillary tube was then modified with 10 mM Sulfo-LC-SPDP. After one hour incubation, the crosslinked capillary tube was rinsed twice with Coupling Buffer (50mM Phosphate, 150mM NaCl, 10mM EDTA, pH 7.2). The Sulfo-LC-SPDP modified capillary tube was filled with 5 μl of the target PLA~2~ consensus peptide (10mg/ml) and incubated overnight at 4^o^C to complete the crosslinking reaction. Phages were panned against target peptide using a modified panning method ([@CIT0004]). Briefly, a Marprene 0.5mm bore 1.6mm wall tubing (Watson-Marlow, Inc., Wilmington, MA) circuit containing a 10μl capillary tube with crosslinked peptide was inserted into a peristaltic pump (Heidolph North America, Elk Grove Village, IL). The tubing circuit was blocked for one hour with Blocking Buffer \[100mM NaHCO~3~, (pH 8.6), 5mg/ml bovine serum albumin (BSA)\], then rinsed six times with 1x TBST \[TBS + 0.1% (v/v) Tween-20\]. Phage libraries (PhD -7, -12, -C7C Phage Display Peptide Library Kits, New England Biolabs, Ipswich, MA) were diluted to a working concentration of 1x10^11^ PFU/ml in 1x TBST, added to the circuit, and slowly circulated at a speed of \<5 rpm for one hour at room temperature (RT). The tubing circuit was rinsed ten times with 1x TBST to facilitate removal of non-binding phages. After siphoning off non-binding phages, phages with high affinity to the target peptide were eluted using either Elution Buffer (25mM Dithiothreitol, pH 8.5) at 37^o^C for Ph.D.-7 and Ph.D.-12 libraries or Acidic Elution Buffer \[200mM Glycine-HCl (pH 2.2), 1mg/ml BSA\] at RT for Ph.D.-C7C phage library. Eluted high-affinity phages were collected in Eppendorf tubes and the Ph.D.-C7C eluent was neutralized using 1M Tris-HCl (pH 9.1). The eluate was diluted 1:1000 in phosphate buffered saline (PBS), then serially diluted and titered out for individual plaques on soft agar plates. An aliquot of the primary panning eluate was amplified for a new population of M13 phages up to 1x10^12-13^ PFU/ml for secondary panning. A second round of panning was carried out with a more stringent wash step (5x TBST). Individual phage clones from the secondary panning elute were selected on soft agar plates and amplified as before up to 1x10^12-13^ PFU/ml. These clones were picked separately and grown up individually for PLA~2~ inhibition assay. To monitor the accuracy of panning process, the polyclonal phage isolates from the primary panning were mixed with venom at varying concentrations (3.2x10^12^ PFU/ml and 8x 10^11^ PFU/ml) and their anti-PLA~2~ activity was measured.

Phage harvesting and quantification
-----------------------------------

Phages were harvested and quantified according to the manufacturer's protocol. Briefly, phages were harvested using a polyethylene glycol precipitation method ([@CIT0019]) and resuspended in PBS (pH 7.5). Collected phages were titered on isopropyl β-D-1-thiogalactopyranoside/5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (50mM IPTG/40mM X-Gal) Luria-Bertani medium. Phage clones were individually picked from soft agar titer plates and amplified based on the manufacturer's protocol for further testing.

Venoms
------

Snake venoms \[Western cottonmouth, Eastern diamondback rattlesnake (*Crotalus adamanteus*), Western diamondback rattlesnake (*Crotalus atrox*), Mojave rattlesnake (*Crotalus scutulatus*), and broad-banded copperhead (*Agkistrodon contortrix laticinctus*)\], were obtained in lyophilized form from the National Natural Toxins Research Center (Kingsville, TX). Venoms were reconstituted at a concentration of 10mg/ml in PBS (pH 7.5) and diluted to working concentrations.

PLA~2~ Activity Assay
---------------------

PLA~2~ activity was measured using the EnzChek Phospholipase A~2~ Assay kit (Invitrogen, Eugene, OR) with modification. Briefly, the concentration of Western cottonmouth venom was optimized to be 4.88 mg/ml for the linearity of fluorescence signal from the plate reader. The selected phage clones were diluted to 1x 10^12^ PFU/ml and incubated with Western cottonmouth venom for 30min at RT. A non-specific M13 phage clone was used as a negative control. After adding reaction substrate to phage and venom mixture, fluorescence (excitation at 485nm and emission at 528nm) was measured for 20min at one minute intervals to monitor the reaction. The overall PLA~2~ activity was defined by the fluorescence level at the 10min time point.

Cross-species Inhibition
------------------------

The inhibitory effect of monoclonal phage isolates on venoms beyond Western cottonmouth was determined using the EnzChek Phospholipase A~2~ Assay kit with modification. Venom from the Western cottonmouth, Eastern diamondback rattlesnake, Western diamondback rattlesnake, Mojave rattlesnake, and broad-banded copperhead, was diluted to a working concentration of 4.88μg/ml. Diluted venom was incubated with 1x10^12^ PFU/ml phage clones for 30min at RT. A non-specific M13 phage clone was used as a negative control. After adding reaction substrate to phage and venom mixture, fluorescence (excitation at 485nm and emission at 528nm) was measured for 20min at one minute intervals to monitor the reaction. The overall PLA~2~ activity was defined by the fluorescence level at the 10min time point.

DNA Sequencing
--------------

The double-stranded DNA (dsDNA) replicative form (RF) isolates of monoclonal phage from single plaque-infected ER2738 cultures were extracted using the QIAprep Spin Miniprep Kit (Qiagen, Germantown, MD) following manufacturer's directions. Extracted dsDNA RFs were sequenced upstream of the peptide insertion using the -96 gIII sequencing primer supplied with the Ph.D. Phage Display Peptide Library Kit. DNA sequences were translated to amino acid sequences using the ExPASy Translate tool from the Swiss Institute of Bioinformatics.

Statistical Analysis
--------------------

All experiments were conducted in triplicate and each fluorescence reading from the PLA~2~ reaction mixture was measured from three separate wells. The means and standard deviations were calculated from relative fluorescence units. Student's *t*-test was used to determine the level of significance (*p* \<0.05).

Results
=======

The BLAST report identified a region of 120 amino acids with high consensus. A section of 57 amino acids annotated as the active (yellow highlight) and metal binding site (red characters) for PLA~2~ ([Figure 1a](#F1){ref-type="fig"}) is shown. The section corresponding to the active site was matched to the predicted crystal structure of PLA~2~ (PDB: 1PPA) from Eastern cottonmouth venom, and the surface-exposed residues were annotated ([Figure 1b](#F1){ref-type="fig"}). The consensus peptide used as the panning target shares ≥95% homology with the major North American Crotalid (rattlesnakes, copperheads and cottonmouths) PLA~2~ proteins. During the panning process, polyclonal phage isolates from the primary panning process showed PLA~2~ inhibition activity in a concentration-dependent manner ([Figure 2](#F2){ref-type="fig"}). Two different concentrations of polyclonal anti-PLA~2~ isolates (3.2x10^12^ PFU/ml and 8x10^11^ PFU/ml) were incubated with Western cottonmouth venom, inhibiting PLA~2~ activity by 55% and 15% of uninhibited venom. Since phages from the primary panning showed inhibition of PLA~2~ activity, the secondary panning was conducted with these eluted phages in more stringent conditions (5x TBST). After the second round of phage panning, the eluent was amplified and tested against Western cottonmouth venom again. Four individual phage clones were selected from polyclonal mixture based on their anti-PLA~2~ activity ([Figure 3](#F3){ref-type="fig"}). These clones inhibited 30% to 60% of PLA~2~ activity from Western cottonmouth venom. Phage DNA sequencing from the selected monoclonal isolates identified four unique sequences and their corresponding peptide sequences ([Table 1](#T1){ref-type="table"}). Three of the sequenced isolates were from the Ph.D.-C7C library, showing three circular 7-mer motifs (Ph.D.-C7C-6, Ph.D.-C7C-7, and Ph.D.-C7C-9). The fourth was from the Ph.D.-12 library with a linear 12-mer peptide (Ph.D.-12-7). Cross-species anti-PLA~2~ activity was tested against five major snake venoms in North America (Western cottonmouth, Eastern diamondback rattlesnake, Western diamondback rattlesnake, Mojave rattlesnake, and broad-banded copperhead) using one of selected anti-PLA~2~ clones (Ph.D.-12-7). Results showed approximately 40% inhibition in Western cottonmouth venom and 30% inhibition in the other crotalid venoms ([Figure 4](#F4){ref-type="fig"}).

![*In silico*design of consensus peptide from Cottonmouth PLA~2~. **A.** Homology sequence of PLA~2~ from cottonmouth species. This sequence corresponds to the homologous sequence between three PLA~2~ proteins from cottonmouth species. The yellow section corresponds to the active site and was synthesized as the target molecule for panning. Characters in red are the metal binding site, based on BLAST annotations. **B.** Crystal Structure of *A. p. leucostoma* PLA~2~. The front and 90° counterclockwise rotated views of PLA~2~ are shown. Colored circles annotate shared solvent-exposed residues with the synthesized homologous sequence (red: metal binding site, yellow: active site).](JVR-08-19-g001){#F1}

![activity of polyclonal M13 phages after the primary panning. Two different concentration of polyclonal anti-PLA~2~ M13 phages after the primary panning inhibited 55% and 15% of PLA~2~ activity of Western cottonmouth venom after 30min incubation. \[◾: venom only (4.88μg/ml); ○: venom with 8x10^11^ PFU/ml of anti-PLA~2~ phages; •: venom with 3.2x10^12^ PFU/ml of anti-PLA~2~ phages.\]](JVR-08-19-g002){#F2}

![Anti-PLA~2~ activities of selected M13 phage clones. Incubation with selected phage clones isolated from phage display libraries inhibited the PLA~2~ activity of *A. p. leucostoma* venom by 30-60% during the first 10min. Phage clones were incubated with 4.88μg/ml of venom for 30min.](JVR-08-19-g003){#F3}

###### 

Nucleotide sequences and corresponding peptide sequences of selected monoclonal phage binding motifs.

  **Monoclonal Isolate**   **Nucleotide Sequence**                **Peptide Sequence**
  ------------------------ -------------------------------------- ----------------------
  Ph.D.-C7C-6              TCGCCGTTGCATAAGACTATG                  SPLHKTM
  Ph.D.-C7C-7              TCGGGGATGAAGAAGACGAAG                  SGMKKTK
  Ph.D.-C7C-9              AAGACGACGAAGATGGGGTTG                  KTTKMGL
  Ph.D.-12-7               AAGCTTATTCATGGTAATGGTGTTATGGATGAGGGG   KLIHGNGVMDEG

![Cross-species anti-PLA~2~ activity of Ph.D.-12-7 phages against five major snake venoms in North America. Cross-species anti-PLA~2~ activity was tested against five major snake venoms in North America (Western cottonmouth, Eastern diamondback rattlesnake, Western diamondback rattlesnake, Mojave rattlesnake, and broad-banded copperhead) using one of selected anti-PLA~2~ clones (Ph.D.-12-7). Approximately 40% inhibition in Western cottonmouth venom and 30% inhibition in the other crotalid venoms were observed.](JVR-08-19-g004){#F4}

Discussion
==========

A consensus peptide, based on sequence homologous of PLA~2~ in cottonmouth species venom, proved to be a viable target for the selection of anti-PLA~2~ peptides displayed on M13 phages. Utilizing venom proteomic data, epitope design could be optimized *in silico* to produce a consensus antigenic determinant. This *in silico* approach could enhance the effective selection from a phage display library by targeting areas closely related to the venom activity, in contrast to serum-based methods that produce 5% - 36% therapeutically relevant antibodies ([@CIT0007]). Successful selection of anti-PLA~2~ display phages which can inhibit a major component of Western cottonmouth venom, PLA~2~, could open the door to targeting other venom components, including metalloprotease or serine protease, utilizing this approach. Selection of antivenom phages was completed within four months, including design and synthesis of a novel consensus peptide, panning several Ph.D. libraries, and characterizing inhibitory effects.

While the observed highest inhibitory rate was 60%, a synergistic inhibitory effect could be expected after combining all the selected anti-PLA~2~ phages. Because four unique sequences of selected peptides displayed on M13 phages would target different regions of the PLA~2~ active sites, a more comprehensive inhibitory effect could be observed. Expansion of target venom components is currently underway and the design of consensus peptides for both metalloprotease and serine protease is being formulated. Once inhibitory phages for the three major venom components have been identified, a phage cocktail will be assembled and its synergetic effect will be tested against whole venom in an animal model to confirm the efficacy in practical application. In addition to screening individual venom components in Western cottonmouth venom, the universal consensus sequences of six other venoms from the Crotalidae subfamily have been identified for screening, incorporating features of all seven Crotalidae snake venoms.

Antivenom development and production towards the venom of small animals (eg. scorpion and spider) is hindered by the limited amounts of venom available for collection ([@CIT0008]). In this study, only 5 μl of consensus venom peptide (10 mg/ml) was needed for the panning process. *In silico* design and synthesis of consensus peptides could provide an alternative solution to the limitation of venom availability. Design of *in silico* peptides could utilize transcriptome annotations to identify potential epitopes of unknown or punitive toxins. In addition, the design of consensus peptides could be based on shared homology across several genera or species. A future therapeutic product developed from multiple composite consensus peptides could show general effectiveness across venom components from several snake species in the geographic region. This design methodology could be expanded to include target molecules beyond proteins like carbohydrates and metals that are integral to venom components.

Conclusions
===========

To the best of our knowledge, this is the first report identifying short peptide sequences expressed on M13 phages that can inhibit PLA~2~ activity of Western cottonmouth venom *in vitro*. The phage display methods conducted in this study could be implemented for the development of novel antivenom. Using BLAST search tool and subsequent categorization of venom sequences, the consensus target peptides of multiple peptide families could be systematically selected and used for the development of a universal antivenom covering snakes, reptiles, arachnids, sea jellies, or other venomous species. Future work is needed to investigate the synergetic effects of selected phages on target venom components.
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